Approaches to the management of agents used for the treatment of multiple sclerosis: Consensus statements from a panel of U.S. Managed care pharmacists and physicians

Journal of Managed Care Pharmacy

Volumn 18, Issue 1, 2012, Pages 54-62

  Miller, Ross M ^a   Happe, Laura E ^b,c   Meyer, Kellie L ^c   Spear, Rachel J ^c  

^a CERNER CORPORATION   (United States)

^b PRESBYTERIAN COLLEGE   (United States)

^c XCENDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; BETA1A INTERFERON; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB;

ADMINISTRATIVE PERSONNEL; ARTICLE; CONSENSUS DEVELOPMENT; CONTRACT; DELPHI STUDY; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE SURVEY; HUMAN; INTERNET; MANAGED CARE; MEDICAL EXPERT; MEDICATION THERAPY MANAGEMENT; MULTIPLE SCLEROSIS; PATIENT PREFERENCE; PHARMACIST; PHYSICIAN; RECOMMENDED DRUG DOSE; UNITED STATES;

EID: 84860734644     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2012.18.1.54     Document Type: Article

References (28)

1. Trisolini MG. Comparison of multiple sclerosis guidelines underscores need for collaboration. Agency for Healthcare Research and Quality. December 8, 2008. Available at: http://www.guideline.gov/expert/expertcommentary.aspx?id=16443. Accessed November 13, 2011.
2. National Multiple Sclerosis Society. Available at: http://www.nationalmssociety.org/index.aspx. Accessed November 13, 2011.
3. Bainbridge JL, Corboy JR. Multiple sclerosis. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 7th ed. New York, NY: McGraw-Hill; 2008:913-26.
4. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part 1: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005;4(5):281-88.
5. Wingerchuk DM. Current evidence and therapeutic strategies for multiple sclerosis. Semin Neurol. 2008;28(1):56-68.
6. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;346(3):158-64. Available at: http://www.nejm.org/doi/full/10.1056/NEJMoa011341. Accessed November 13, 2011.
7. Leary SM, Porter B, Thompson AJ. Multiple sclerosis: diagnosis and the management of acute relapses. Postgrad Med J. 2005;81(955):302-08 Available at: http://pmj.bmj.com/content/81/955/302.long. Accessed November 13, 2011.
8. Alonso-Magdelena L, Romero-Pinel L, Moral E, et al. Anticipation of age at onset in multiple sclerosis: methodologic pitfalls. Acta Neurol Scand. 2010;121(6):426-28.
9. U.S. Census Bureau, Current Population Survey, 2010 Annual Social and Economic Supplement. Available at: http://www.census.gov/hhes/www/cpstables/032010/health/h05_000.htm. Accessed November 13, 2011.
10. Asche CV, Singer ME, Jhaveri M, Chung H, Miller A. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm. 2010;16(9):703-12. Available at: http://www.amcp.org/data/jmcp/703-712.pdf.
11. Schafer JA, Gunderson BW, Gleason PP. Price increases and new drugs drive increased expenditures for multiple sclerosis. J Manag Care Pharm. 2010;16(9):713-17. Available at: http://www.amcp.org/data/jmcp/713-717.pdf.
12. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169-78. Available at: http://www.aan.com/professionals/practice/pdfs/gl0091.pdf. Accessed November 13, 2011.
13. Coleman IC, Cook R, Gade JN, et al. Meeting the challenge of incorporating injectable biologics into managed care: multiple sclerosis and psoriasis. J Manag Care Pharm. 2004;10(3)(Suppl S-b):S1-S45. Available at: http://www.amcp.org/data/jmcp/June04Supplement1.pdf.
14. Copaxone (glatiramer acetate injection) solution for subcutaneous injection. Teva Neuroscience, Inc. February 2009. Available at: http://www.sharedsolutions.com/pdfs/PrescribingInformation.aspx. Accessed November 13, 2011.
15. Extavia (interferon beta-1b) for subcutaneous injection. Novartis Pharmaceuticals Corporation. August 2009. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/extavia.pdf. Accessed November 13, 2011.
16. Betaseron (interferon beta-1b) for subcutaneous injection. Bayer HealthCare Pharmaceuticals. May 2010. Available at: http://berlex.bayerhealthcare.com/html/products/pi/Betaseron_PI.pdf. Accessed November 13, 2011.
17. Avonex (interferon beta-1a) for IM injection. Biogen Idec Inc. June 2011. Available at: http://www.avonex.com/pdfs/pi-syringe.pdf. Accessed November 13, 2011.
18. Rebif (interferon beta-1a) for subcutaneous injection. EMD Serono, Inc. September 2009. Available at: http://media.pfizer.com/files/products/uspi_rebif.pdf. Accessed November 13, 2011.
19. Tysabri (natalizumab) injection for intravenous use. Biogen Idec Inc. September 2011. Available at: http://www.tysabri.com/en_US/tysb/site/pdfs/TYSABRI-pi.pdf. Accessed November 13, 2011.
20. Gilenya (fingolimod) capsules. Novartis Pharmaceuticals Corporation. July 2011. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf. Accessed November 13, 2011.
21. Ampyra (dalfampridine) extended release tablets. Acorda Therapeutics, Inc. January 2010. Available at: http://ampyra-hcp.com/local/files/PI.pdf. Accessed November 13, 2011.
22. McKenna H. The Delphi technique: a worthwhile approach for nursing? J Adv Nurs. 1994;19(6):1221-25.
23. Hasson F, Keeney S, McKenna HP. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000;32(4):1008-15.
24. Keeney S, Hasson F, McKenna H. A critical review of the Delphi technique as a research methodology for nursing. Int J Nurs Stud. 2001;38(2):195-200.
25. Brook R, Chassin M, Fink A, Solomon DH, Kosecoff J, Park RE. A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care. 1986;2(1):53-63.
26. Wyrich KW, Spertus JA, Kroenke K, Tierney WM, Babu AN, Wolinsky FD. Clinically important differences in health status for patients with heart disease: an expert consensus panel report. Am Heart J. 2004;147(4):615-22.
27. National Institute for Clinical Excellence. Multiple sclerosis (relapsingremitting) - fingolimod. September 7, 2011. Available at: http://guidance.nice.org.uk/TA/Wave20/71. Accessed November 13, 2011.
28. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68(3):295-303.